Statins promote potent systemic antioxidant effects through specific inflammatory pathways

MH Shishehbor, ML Brennan, RJ Aviles, X Fu… - Circulation, 2003 - Am Heart Assoc
MH Shishehbor, ML Brennan, RJ Aviles, X Fu, MS Penn, DL Sprecher, SL Hazen
Circulation, 2003Am Heart Assoc
Background—The pleiotropic actions of hydroxymethylglutaryl CoA reductase inhibitors
(statins) include antiinflammatory and antioxidant actions. We recently reported that statins
induce reductions in plasma protein levels of nitrotyrosine (NO2Tyr), a modification
generated by nitric oxide–derived oxidants. Whether alternative oxidative pathways are
suppressed in vivo after statin administration has not yet been reported. Methods and
Results—As an extension of our prior study, hypercholesterolemic subjects with no known …
Background— The pleiotropic actions of hydroxymethylglutaryl CoA reductase inhibitors (statins) include antiinflammatory and antioxidant actions. We recently reported that statins induce reductions in plasma protein levels of nitrotyrosine (NO2Tyr), a modification generated by nitric oxide–derived oxidants. Whether alternative oxidative pathways are suppressed in vivo after statin administration has not yet been reported.
Methods and Results— As an extension of our prior study, hypercholesterolemic subjects with no known coronary artery disease were evaluated at baseline and after 12 weeks of atorvastatin therapy (10 mg/d). Plasma levels of protein-bound chlorotyrosine, NO2Tyr, dityrosine, and orthotyrosine, specific molecular fingerprints for distinct oxidative pathways upregulated in atheroma, were determined by mass spectrometry. In parallel, alterations in lipoproteins and C-reactive protein were determined. Statin therapy caused significant reductions in chlorotyrosine, NO2Tyr, and dityrosine (30%, 25%, and 32%, respectively; P<0.02 each) that were similar in magnitude to reductions in total cholesterol and apolipoprotein B-100 (25% and 29%, P<0.001 each). Nonsignificant decreases in orthotyrosine and C-reactive protein levels were observed (9% and 11%, respectively; P>0.10 each). Statin-induced reductions in oxidation markers were independent of decreases in lipids and lipoproteins.
Conclusions— Statins promote potent systemic antioxidant effects through suppression of distinct oxidation pathways. The major pathways inhibited include formation of myeloperoxidase-derived and nitric oxide–derived oxidants, species implicated in atherogenesis. The present results suggest potential mechanisms that may contribute to the beneficial actions of statins. They also have important implications for monitoring the antiinflammatory and antioxidant actions of these agents.
Am Heart Assoc